We are live on ! Find out more
CCM

Catalio Capital Management Portfolio holdings

AUM $479M
1-Year Est. Return 140.7%
This Fund
S&P 500
This Quarter Est. Return
-2.44%
1 Year Est. Return
+140.7%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$411M
AUM Growth
-$46M
Cap. Flow
-$1.26M
Cap. Flow %
-0.31%
Top 10 Hldgs %
68.26%
Holding
46
New
13
Increased
7
Reduced
7
Closed
9

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$24.5M
2
LLY icon
Eli Lilly
LLY
+$19.7M
3
INSP icon
Inspire Medical Systems
INSP
+$15.5M
4
BDX icon
Becton Dickinson
BDX
+$12.8M
5
VCYT icon
Veracyte
VCYT
+$10.4M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$28.2M
2
BPMC
Blueprint Medicines
BPMC
+$24.8M
3
NVST icon
Envista
NVST
+$19.7M
4
EXAS
Exact Sciences
EXAS
+$17.4M
5
MASI
Masimo
MASI
+$14.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZBIO
26
Zenas BioPharma
ZBIO
$2.05B
$2.33M 0.57%
295,148
+107,964
+58% +$845K
OM icon
27
Outset Medical
OM
$90.8M
$1.84M 0.45%
+166,666
New +$1.99M
ARQT icon
28
PUT
Arcutis Biotherapeutics
ARQT
$3.18B
$1.25M 0.3%
+100,000
New +$1.41M
KYTX icon
29
Kyverna Therapeutics
KYTX
$484M
$1.13M 0.28%
586,909
– –
MGX icon
30
Metagenomi Therapeutics
MGX
$46.3M
$719K 0.18%
528,993
– –
MRSN
31
DELISTED
Mersana Therapeutics
MRSN
$587K 0.14%
68,201
– –
FULC icon
32
Fulcrum Therapeutics
FULC
$297M
$582K 0.14%
+202,139
New +$742K
KPTI icon
33
Karyopharm Therapeutics
KPTI
$48M
$582K 0.14%
155,622
-3
-0% -$26
HYPR icon
34
Hyperfine
HYPR
$101M
$544K 0.13%
760,035
– –
ATAI icon
35
AtaiBeckley Inc
ATAI
$2.68B
$268K 0.07%
196,858
– –
GUTS icon
36
Fractyl Health
GUTS
$111M
$255K 0.06%
214,236
– –
FTH
37
Faeth Therapeutics
FTH
$629M
$116K 0.03%
14,719
– –
ADMA icon
38
ADMA Biologics
ADMA
$2.22B
– –
-512,724
Closed -$8.79M
BMY icon
39
Bristol-Myers Squibb
BMY
$132B
– –
-499,151
Closed -$28.2M
BPMC
40
DELISTED
Blueprint Medicines
BPMC
– –
-284,654
Closed -$24.8M
BSX icon
41
Boston Scientific
BSX
$71.5B
– –
-72,925
Closed -$6.51M
EXAS
42
DELISTED
Exact Sciences
EXAS
– –
-309,103
Closed -$17.4M
IRON icon
43
Disc Medicine
IRON
$2.97B
– –
-179,815
Closed -$11.4M
MASI
44
DELISTED
Masimo
MASI
– –
-87,377
Closed -$14.4M
NVST icon
45
Envista
NVST
$4.52B
– –
-1,019,529
Closed -$19.7M
NARI
46
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-132,545
Closed -$6.77M
1
2

Similar funds

FFG
Frisch Financial Group Melville, New York $478M AUM 16.28% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return
DA
Dash Acquisitions Woodland Hills, California $480M AUM 4.07% 1-Year Est. Return
NQWM
Northwest Quadrant Wealth Management Bend, Oregon $481M AUM 13.55% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $481M AUM 46% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM

Catalio Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Catalio Capital Management held 46 positions worth $411M, down 10% from $457M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Catalio Capital Management's Q1 2025 filing shows 13 new, 7 increased, 7 reduced and 9 closed positions. Its largest new stake was Syndax Pharmaceuticals: 1,733,701 shares worth $21.3M. The largest sale was Bristol-Myers Squibb, an estimated $28.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

  • Catalio Capital Management's largest Q1 2025 buy was Syndax Pharmaceuticals: 1,733,701 shares worth $21.3M.
  • Catalio Capital Management added most to Becton Dickinson in Q1 2025, an estimated $12.8M increase.
  • Catalio Capital Management's biggest Q1 2025 reduction was LivaNova, cutting an estimated $5.87M.
  • Catalio Capital Management fully exited Bristol-Myers Squibb in Q1 2025, selling an estimated $28.2M.
  • Catalio Capital Management's ten largest holdings make up 68% of its $411M portfolio in Q1 2025.
  • Catalio Capital Management opened 13 new positions and closed 9 in Q1 2025.
  • Catalio Capital Management's portfolio value fell 10% quarter-over-quarter to $411M.

Based on Catalio Capital Management's 13F filing for Q1 2025, filed 15 May 2025.